CY1123769T1 - Νουκλεϊκα οξεα για την αγωγη αλλεργιων - Google Patents

Νουκλεϊκα οξεα για την αγωγη αλλεργιων

Info

Publication number
CY1123769T1
CY1123769T1 CY20201101107T CY201101107T CY1123769T1 CY 1123769 T1 CY1123769 T1 CY 1123769T1 CY 20201101107 T CY20201101107 T CY 20201101107T CY 201101107 T CY201101107 T CY 201101107T CY 1123769 T1 CY1123769 T1 CY 1123769T1
Authority
CY
Cyprus
Prior art keywords
vaccines
nucleic acids
protein
lamp
allergenic
Prior art date
Application number
CY20201101107T
Other languages
Greek (el)
English (en)
Inventor
William Hearl
Teri Heiland
Original Assignee
Immunomic Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomic Therapeutics, Inc. filed Critical Immunomic Therapeutics, Inc.
Publication of CY1123769T1 publication Critical patent/CY1123769T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CY20201101107T 2012-06-15 2020-11-23 Νουκλεϊκα οξεα για την αγωγη αλλεργιων CY1123769T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/042552 WO2013187906A1 (en) 2012-06-15 2012-06-15 Nucleic acids for treatment of allergies

Publications (1)

Publication Number Publication Date
CY1123769T1 true CY1123769T1 (el) 2022-05-27

Family

ID=49758576

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101107T CY1123769T1 (el) 2012-06-15 2020-11-23 Νουκλεϊκα οξεα για την αγωγη αλλεργιων

Country Status (20)

Country Link
US (3) US9744230B2 (OSRAM)
EP (2) EP3808361A1 (OSRAM)
JP (1) JP5807994B2 (OSRAM)
KR (2) KR102107646B1 (OSRAM)
CN (2) CN104519896B (OSRAM)
AU (3) AU2012382406B2 (OSRAM)
BR (1) BR112014031327B1 (OSRAM)
CA (1) CA2876824C (OSRAM)
CY (1) CY1123769T1 (OSRAM)
DK (1) DK2861240T3 (OSRAM)
ES (1) ES2831723T3 (OSRAM)
HR (1) HRP20201815T1 (OSRAM)
HU (1) HUE052481T2 (OSRAM)
IL (4) IL236174B (OSRAM)
LT (1) LT2861240T (OSRAM)
PL (1) PL2861240T3 (OSRAM)
PT (1) PT2861240T (OSRAM)
RS (1) RS61098B1 (OSRAM)
SI (1) SI2861240T1 (OSRAM)
WO (1) WO2013187906A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160185831A1 (en) * 2011-06-14 2016-06-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
PL2861240T3 (pl) 2012-06-15 2021-07-05 Immunomic Therapeutics, Inc. Kwasy nukleinowe do leczenia alergii
US11096994B2 (en) 2012-10-30 2021-08-24 Aravax Pty Ltd Immunotherapeutic molecules and uses thereof
JP7007534B2 (ja) 2013-09-25 2022-01-24 アラヴァックス ピーティーワイ リミテッド 新規免疫療法組成物およびその使用
BR112016030439A2 (pt) * 2014-06-23 2018-07-17 Immunomic Therapeutics Inc ácidos nucléicos para o tratamento de alergias ao amendoim.
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
EP3901254A1 (en) 2015-12-23 2021-10-27 Medigene Immunotherapies GmbH Novel generation of antigen-specific tcrs
CN110418650A (zh) * 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
BR112019022108A2 (pt) 2017-04-22 2020-05-12 Immunomic Therapeutics, Inc. Construções de lamp aprimoradas
KR20200016224A (ko) * 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
AU2018302153B2 (en) 2017-07-18 2024-04-18 Société des Produits Nestlé S.A. Methods for making mixed allergen compositions
CN111936856A (zh) * 2018-04-06 2020-11-13 Sls生物有限公司 新型免疫球蛋白e的表位、与其结合的抗体及包括所述抗体的用于分析试料中免疫球蛋白e的试剂盒
MX2020012055A (es) * 2018-05-11 2021-01-29 Astellas Pharma Inc Acido nucleico para el tratamiento de alergia por crustaceos.
EP3795688A4 (en) * 2018-05-11 2022-01-19 Astellas Pharma Inc. Nucleic acid for treating mite allergy
CA3100004A1 (en) * 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
CN113507844A (zh) 2019-01-23 2021-10-15 前品牌股份有限公司 制备混合型过敏原组合物的方法
WO2020186190A2 (en) * 2019-03-13 2020-09-17 Psomagen, Inc. Epitope-based approach for allergy treatments and inhibitors for crohn's disease
US12150461B2 (en) * 2021-05-04 2024-11-26 Sovida Solutions Ltd. Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof
JP2023024410A (ja) * 2021-08-06 2023-02-16 花王株式会社 Ｓｎａｒｅを活用した核酸構築物
FI20237105A1 (en) 2023-05-29 2024-11-30 Onni Biotechnologies Oy Modified natural killer cells with enhanced cytotoxic action and greater survival

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD335810S (en) 1990-07-02 1993-05-25 Dick-Ming Asien Handle for luggage or similar article
US6090386A (en) 1991-07-12 2000-07-18 Griffith; Irwin J. T cell peptides of the CRX JII allergen
US6982326B1 (en) 1991-07-12 2006-01-03 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from Japanese cedar pollen
WO1994024281A1 (en) * 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
CA2148713A1 (en) * 1992-11-12 1994-05-26 Mei-Chang Kuo Allergenic proteins and peptides from japanese cedar pollen
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
JP3649460B2 (ja) 1993-11-05 2005-05-18 明治乳業株式会社 スギ花粉アレルゲンＣｒｙ ｊ ＩＩエピトープ
GB9516760D0 (en) 1995-08-16 1995-10-18 Sandoz Ltd Organic compounds
CA2241918C (en) 1995-12-29 2008-12-02 University Of Arkansas Peanut allergens and methods
CA2258125C (en) 1996-06-14 2010-11-23 Meiji Milk Products Co., Ltd. T-cell epitope peptides
US20020142978A1 (en) * 2000-04-07 2002-10-03 Eyal Raz Synergistic improvements to polynucleotide vaccines
AU2002306850A1 (en) 2001-03-16 2002-10-03 Panacea Pharmaceuticals Methods and reagents for decreasing clinical reaction to allergy
US8318173B2 (en) * 2001-04-05 2012-11-27 The John Hopkins University Chimeric vaccines
US20060003148A1 (en) 2004-06-30 2006-01-05 Zwynenburg James L Interlocking polymeric foam floor underlayment and process for making
US20060216315A1 (en) * 2005-03-16 2006-09-28 Yoo Tai J Cockroach allergen gene expression and delivery systems and uses
WO2006138435A2 (en) 2005-06-16 2006-12-28 Mount Sinai School Of Medicine Methods for enhancing immune responses
US7566456B2 (en) 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
WO2007024026A1 (ja) * 2005-08-25 2007-03-01 Taiho Pharmaceutical Co., Ltd. Ｔ細胞認識エピトープペプチドを固定化又は内包化した生分解性ナノ粒子
US20080006554A1 (en) 2006-07-07 2008-01-10 Medtronic Vascular, Inc. Packaging assembly for a catheter
EP2042193A1 (en) * 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
CN102186880A (zh) * 2008-09-10 2011-09-14 Ith免疫治疗控股股份公司 炎症的治疗
PL2861240T3 (pl) * 2012-06-15 2021-07-05 Immunomic Therapeutics, Inc. Kwasy nukleinowe do leczenia alergii
CN110418650A (zh) * 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
BR112019022108A2 (pt) * 2017-04-22 2020-05-12 Immunomic Therapeutics, Inc. Construções de lamp aprimoradas

Also Published As

Publication number Publication date
IL270260B (en) 2020-08-31
EP2861240A4 (en) 2016-03-16
BR112014031327B1 (pt) 2022-02-01
LT2861240T (lt) 2021-01-25
ES2831723T3 (es) 2021-06-09
CA2876824C (en) 2020-07-21
AU2018200625A1 (en) 2018-02-15
EP2861240A1 (en) 2015-04-22
PT2861240T (pt) 2020-11-09
IL270261B (en) 2021-03-25
SI2861240T1 (sl) 2021-04-30
PL2861240T3 (pl) 2021-07-05
US20160271245A1 (en) 2016-09-22
HRP20201815T1 (hr) 2021-02-19
AU2019250227B2 (en) 2021-10-21
CN107937423A (zh) 2018-04-20
CN104519896B (zh) 2017-11-10
KR20200047792A (ko) 2020-05-07
JP2015521467A (ja) 2015-07-30
KR20150032286A (ko) 2015-03-25
AU2018200625B2 (en) 2019-09-19
EP2861240B1 (en) 2020-09-09
AU2012382406A2 (en) 2015-04-16
WO2013187906A1 (en) 2013-12-19
RS61098B1 (sr) 2020-12-31
JP5807994B2 (ja) 2015-11-10
CA2876824A1 (en) 2013-12-19
US20220081474A1 (en) 2022-03-17
EP3808361A1 (en) 2021-04-21
AU2012382406A1 (en) 2014-12-18
US10072053B2 (en) 2018-09-11
AU2019250227A1 (en) 2019-11-07
US9744230B2 (en) 2017-08-29
IL270262A (en) 2019-12-31
IL236174B (en) 2019-11-28
BR112014031327A2 (pt) 2017-06-27
KR102386481B1 (ko) 2022-04-14
HUE052481T2 (hu) 2021-04-28
CN104519896A (zh) 2015-04-15
AU2012382406B2 (en) 2017-12-07
DK2861240T3 (da) 2020-09-28
US20180009857A1 (en) 2018-01-11
KR102107646B1 (ko) 2020-05-08
IL236174A0 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
CY1123769T1 (el) Νουκλεϊκα οξεα για την αγωγη αλλεργιων
WO2015200357A3 (en) Nucleic acids for treatment of peanut allergies
CY1121691T1 (el) Εξατομικευμενη ανοσοθεραπεια εναντι ογκων των νευρωνων και του εγκεφαλου
CY1125084T1 (el) Εμβολια νουκλεϊκου οξεος
CY1120740T1 (el) Βελτιωμενα ευλογοϊικα εμβολια
BR112013020070A8 (pt) moléculas de ácido nucleico que codificam novos antígenos de herpes, vacina compreendendo as mesmas e métodos de uso das mesmas
WO2018093932A3 (en) Nucleic acids for treatment of allergies
CY1122035T1 (el) Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων
CY1124979T1 (el) Κατασκευασματα πρωτεϊνης uspa2 και χρησεις αυτων
MX421208B (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
EA202090759A2 (ru) Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина
CY1110178T1 (el) Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ι ή ιι για εμβολια
EA201201025A1 (ru) Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них
EA201391240A1 (ru) Слитые белки и комбинированные вакцины, содержащие белок е и пилин а haemophilus influenza
CY1123520T1 (el) Μεθοδοι για την προβλεψη της χρησιμοτητας των νεων αντιγονων για ανοσοθεραπεια
CY1124707T1 (el) Συνθεσεις και μεθοδοι για την επαγωγη ενισχυμενης ανοσοαποκρισης με χρηση φορεων ιων poxvirus (ευλογοϊων)
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
MX2017015404A (es) Visualizacion de superficie de antigenos en vesiculas de membrana externa gram-negativas.
EP4512477A3 (en) Improved lamp constructs
CY1124685T1 (el) Εξατομικευμενα εμβολια για τον καρκινο
MX2014011242A (es) Vacunas de conjugado carbohidrato-glicolipido.
MA37749A1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
MX363149B (es) Vacunas de nucleoproteina de la influenza.
BR112018001148A2 (pt) heterômeros compreendendo proteínas de fusão com domínios de anticorpos
CO2018007442A2 (es) Vacunas contra el cáncer